“We expect third quarter revenue growth to be approximately 2%-3%, which includes an approximately 250 basis point year-over-year headwind from respiratory testing.”

In context

“ssays. This strong performance was supported by continued adoption of recent menu expansions, including the Multiplex GI panel, as well as several notable key account wins with large hospital networks. Respiratory revenue was in line with our expectations for the second quarter, though down year-over-year due to lower seasonal infection rates. During the quarter, Cepheid supported the Ebola outbreak response in the Democratic Republic of Congo and Uganda through the donation of Xpert Hemorrhagic Fever panel tests. Working with global health partners, Cepheid's decentralized GeneXpert platform is helping expand testing capacity in affected regions and support faster isolation, treatment, and containment of this deadly virus. Moving to how we are thinking about the second half of the year. We expect third quarter revenue growth to be approximately 2%-3%, which includes an approximately 250 basis point year-over-year headwind from respiratory testing. This implies that core growth excluding respiratory will be approximately 5%, an acceleration versus what we saw in the second quarter. We continue to expect to exit Q4 at the mid-single digit core revenue growth rate as we move past some of the headwinds from the first three quarters of the year. This results in a full year 2026 core revenue growth outlook in the range of 3%-4%. Our updated outlook reflects higher anticipated core revenue growth in our life sciences segment as we expect these markets to recover faster than our initial expectations, offset by a slightly more conservative outlook for bioprocessing, given some of the customer-driven timing dynamics we saw in the second quarter. Additionally, given our second quarter earnings beat and the earlier than anticipated completion”